Eli Lilly CEO David Ricks (L) and Sanofi CEO Paul Hudson at a Senate hearing entitled 'The Need to Make Insulin Affordable for All Americans' (Al Drago/Bloomberg via Getty Images)

August 31, 2023 04:11 PM EDTUpdated September 1, 10:59 AM

FDA+

Lilly, Novo, Sanofi face pressure from lawmakers to clarify low-cost insulin programs

Lia DeGroot

Sens. Maggie Hassan (D-NH) and Tina Smith (D-MN) are asking the three major insulin manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — to provide more details …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

view job offer post your job now

TRENDING NOW

Lilly, Novo, Sanofi face pressure from lawmakers to clarify low-cost insulin programs

Lia DeGroot

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development

Lil­ly, No­vo, Sanofi face pres­sure from law­mak­ers to clar­i­fy low-cost in­sulin pro­grams

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lilly, Novo, Sanofi face pressure from lawmakers to clarify low-cost insulin programs